Interpace CFO gets options on 277K shares at $2.02

Q: What equity awards did IDXG grant to Christopher McCarthy on August 20, 2026?

Christopher McCarthy received 554,018 RSUs and a stock option for 277,009 shares of INTERPACE BIOSCIENCES, INC. common stock on August 20, 2026, as disclosed in the Form 4.

Q: How many IDXG RSUs vested immediately for Christopher McCarthy and how many are deferred?

Of the 554,018 RSUs granted, 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to Christopher McCarthy’s continued service on that vesting date.

Q: What are the key terms of Christopher McCarthy’s new stock option from IDXG?

The stock option covers 277,009 shares of INTERPACE BIOSCIENCES, INC. common stock at an exercise price of $2.02 per share, expiring on August 20, 2036. It vests in four equal annual installments beginning August 20, 2027, subject to continued service.

INTERPACE BIOSCIENCES, INC.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

INTERPACE BIOSCIENCES, INC. (IDXG) reported equity compensation transactions for CFO & COO Christopher McCarthy on August 20, 2026. He was granted 554,018 RSUs, of which 277,009 vested immediately and converted into common stock, with 277,009 RSUs scheduled to vest on August 20, 2027, subject to continued service. He also received a stock option for 277,009 shares of common stock at an exercise price of $2.02 per share, expiring August 20, 2036, vesting in four equal annual installments beginning August 20, 2027. After these transactions, he directly held 323,800 shares of common stock.

Insider Trade Summary

277,009 shares exercised/converted

Exercise 4 txns

Insider McCarthy Christopher

Role CFO & COO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units ^{F2, F3}	554,018	$0.00	$0.00
Exercise	Restricted Stock Units ^{F2, F3}	277,009	$0.00	$0.00
Grant/Award	Stock Option (right to buy) ^F4	277,009	$0.00	$0.00
Exercise	Common Stock ^F1	277,009	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 277,009 contracts (Direct); Stock Option (right to buy) — 277,009 contracts (Direct); Common Stock — 323,800 shares (Direct)

Footnotes (4)

F1. Represents the conversion upon vesting of restricted stock units (RSUs) into shares of common stock of Interpace Biosciences, Inc. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.
F2. Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.
F3. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.
F4. The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

RSUs granted: 554,018 RSUs RSUs vested immediately: 277,009 RSUs RSUs vesting later: 277,009 RSUs +4 more

7 metrics

RSUs granted 554,018 RSUs Grant to Christopher McCarthy on August 20, 2026

RSUs vested immediately 277,009 RSUs Portion of RSU grant vesting upon grant on August 20, 2026

RSUs vesting later 277,009 RSUs Scheduled to vest on August 20, 2027, subject to continued service

Stock options granted 277,009 options Stock option grant on August 20, 2026

Option exercise price $2.02 per share Exercise price of stock options granted to Christopher McCarthy

Option expiration date August 20, 2036 Expiration of stock options granted on August 20, 2026

Common shares held after transaction 323,800 shares Direct holdings of common stock after August 20, 2026 transactions

Key Terms

Restricted Stock Units, Stock Option, vesting, exercise or conversion of derivative security

4 terms

Restricted Stock Units financial

"Represents the conversion upon vesting of restricted stock units (RSUs) into shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option financial

"The options will vest in four equal annual installments beginning on August 20, 2027"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vesting financial

"of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did IDXG grant to Christopher McCarthy on August 20, 2026?

Christopher McCarthy received 554,018 RSUs and a stock option for 277,009 shares of INTERPACE BIOSCIENCES, INC. common stock on August 20, 2026, as disclosed in the Form 4.

How many IDXG RSUs vested immediately for Christopher McCarthy and how many are deferred?

Of the 554,018 RSUs granted, 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to Christopher McCarthy’s continued service on that vesting date.

What are the key terms of Christopher McCarthy’s new stock option from IDXG?

The stock option covers 277,009 shares of INTERPACE BIOSCIENCES, INC. common stock at an exercise price of $2.02 per share, expiring on August 20, 2036. It vests in four equal annual installments beginning August 20, 2027, subject to continued service.

How many IDXG common shares did Christopher McCarthy hold after the reported transactions?

Following the August 20, 2026 transactions, Christopher McCarthy directly held 323,800 shares of INTERPACE BIOSCIENCES, INC. common stock, according to the Form 4.

How did the RSU grant for IDXG convert into common stock for Christopher McCarthy?

Each RSU represents the right to receive the economic equivalent of one share of common stock. On August 20, 2026, 277,009 RSUs vested and converted into 277,009 shares of INTERPACE BIOSCIENCES, INC. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/20/2026 - 04:59 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Christopher

(Last)

(First)

(Middle)

C/O INTERPACE BIOSCIENCES, INC.

2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310

(Street)

PARSIPPANY

NEW JERSEY

07054

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTERPACE BIOSCIENCES, INC. [ IDXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO & COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/20/2026		M		277,009⁽¹⁾	A	$0	323,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽²⁾	08/20/2026		A		554,018		⁽³⁾	⁽³⁾	Common Stock	554,018	$0	554,018	D
Restricted Stock Units	⁽²⁾	08/20/2026		M			277,009	⁽³⁾	⁽³⁾	Common Stock	277,009	$0	277,009	D
Stock Option (right to buy)	$2.02	08/20/2026		A		277,009		⁽⁴⁾	08/20/2036	Common Stock	277,009	$0	277,009	D

Explanation of Responses:

1. Represents the conversion upon vesting of restricted stock units (RSUs) into shares of common stock of Interpace Biosciences, Inc. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.

2. Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

3. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.

4. The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Christopher McCarthy	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR